Amneal Pharmaceuticals, Inc. AMRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $1.75B+2.7% | $1.75B+3.6% | $1.75B+8.3% | $1.71B+10.3% | $1.71B+14.3% | |
| AvKARE | $738.33M+9.8% | $744.73M+12.3% | $704.37M+9.7% | $665.33M+8.3% | $672.7M+17.5% | |
| Net revenue by Product | ||||||
| Auto-Injector | $226.55M+5.4% | $232.8M+11.1% | $231.6M+9.3% | $223.35M+23.2% | $215.04M+31.7% | |
| Biosimilar | $93.99M-26.1% | $100.23M-20.1% | $109.35M+5.8% | $123.02M+38.0% | $127.27M+67.2% | |
| Central nervous system | $349.19M+24.0% | $333.42M+19.0% | $305.26M— | $301.03M— | $281.51M— | |
| Distribution | $392.71M-8.5% | $408.46M-5.9% | $407.3M-4.4% | $412.69M+1.6% | $429.16M+14.8% | |
| Government label | $279.91M+59.8% | $270.11M+68.9% | $230.17M+55.8% | $184.35M+33.0% | $175.15M+32.4% | |
| Hormonal / allergy | $156.66M+15.8% | $154.93M+18.8% | $144.3M— | $138.89M— | $135.25M— | |
| Injectable | $176.39M+6.9% | $161.24M-2.5% | $171.76M+12.3% | $160.56M+10.6% | $165M+16.5% | |
| Institutional | $34.19M-20.3% | $35.38M-17.2% | $37.72M-9.4% | $41.27M-3.6% | $42.9M+7.2% | |
| International | $16.21M+91.5% | $12.13M+35.4% | $10.72M+30.7% | $8.94M+111% | $8.47M+153% | |
| Oral liquid | $61.37M-35.4% | $72.82M-29.6% | $82.7M-22.2% | $88.82M-20.4% | $95.04M-17.5% | |
| Oral solid | $718.53M+2.8% | $726.38M+5.4% | $720.63M+7.7% | $701.38M+4.6% | $699.08M+6.4% | |
| Other dosage forms | $242.61M+12.7% | $252.42M+24.8% | $243.24M+29.2% | $234.23M+28.1% | $215.34M+20.5% | |
| Other therapeutic classes | $47.13M+57.1% | $39.66M+38.6% | $32.36M— | $30.35M— | $30.01M— | |
| Subtotal dosage forms | $1.74B+2.2% | $1.73B+3.4% | $1.74B+8.2% | $1.71B+10.0% | $1.7B+14.0% | |
| Subtotal therapeutic classes | $552.98M+23.8% | $528.01M+20.2% | $481.92M+15.8% | $470.27M+17.6% | $446.76M+13.5% | |
| Transdermal | $218.41M+19.1% | $187.51M+3.6% | $178.18M+2.5% | $174.47M+2.8% | $183.46M+14.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
